Vicore and Endeavor’s therapies show promise in treating IPF
Both drugs have the potential to offer a disease-modifying approach to the lung disease
Read More
Tag: Vicore Pharma
Vicore Pharma’s DTx to benefit pulmonary fibrosis patients
The nine-week DTxl CBT helps to address psychological symptom burdens in PF patients
Read More
Vicore Pharma’s C21 med shows promise in COVID-19 study
Drug is being studied in hospitalised COVID-19 patients
Read More
- Bioxytran reports positive phase 1b/2a results for antiviral ProLectin‑M
- FDA approves once‑weekly Sogroya for wider paediatric use
- SolasCure trial shows faster healing with Aurase Wound Gel
- Gilead data show investigational HIV combination maintains viral suppression
- Verdiva Bio completes enrolment for phase 2b study of oral GLP‑1 candidate VRB‑101
